Advertisement
Screener

PULMATRIX, INC. (PULM) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

1.5 / 5 stars · 21/68 Roast Me

PULMATRIX, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value

PULMATRIX, INC. (PULM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $4.79 per share for the 12-month period ending 2015-03-31, per its 10-K filed 2015-06-10.

Discontinued › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2015-06-10

  • PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2014-12-31 was $0.00.
  • PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2014-09-30 was $0.00.
  • PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2014-06-30 was $4.79.
  • PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2013-12-31 was $0.00.
  • PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2015 was $4.79.
  • PULMATRIX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2014 was $0.00.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month
2015-03-31$4.79
10-K · filed 2015-06-10
2014-12-31$0.00
10-Q · filed 2015-02-13
$4.79
10-Q · filed 2015-02-13
2014-09-30$0.00
10-Q · filed 2014-11-13
$4.79
10-Q · filed 2014-11-13
2014-06-30$4.79
10-Q · filed 2014-08-14
2014-03-31$0.00
10-K · filed 2015-06-10
2013-12-31$0.00
10-Q · filed 2015-02-13
$0.00
10-Q · filed 2015-02-13
2013-09-30$0.00
10-Q · filed 2014-11-13
$0.00
10-Q · filed 2014-11-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Ernexa Therapeutics Inc. (ERNA)United States$0.006B
ProPhase Labs, Inc. (PRPH)United States$0.006B-0.06
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
Enveric Biosciences, Inc. (ENVB)United States$0.007B-0.63
Bolt Biotherapeutics, Inc. (BOLT)United States$0.007B-0.26
SYNLOGIC, INC. (SYBX)United States$0.007B
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
Acurx Pharmaceuticals, Inc. (ACXP)United States$0.007B-0.97
AMARIN CORP PLC\UK (AMRN)$0.005B-247.24
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B